New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance
By optimizing nature’s defenders, the team has produced unprecedented phage treatments
Advertisement
The new biotech venture PHIOGEN is a spin-off company from Baylor College of Medicine’s TAILOR Labs, one of the United States only academic phage therapy cores with a decade’s worth of revolutionary research related to bacteriophages, viruses that infect and destroy bacteria.
The company made its debut at the 6th World Conference on Targeting Phage Therapy in Paris, June 1-2, 2023.
PHIOGEN’s R&D efforts are led by phage researcher Dr. Anthony Maresso, founder of TAILOR Labs and associate professor of molecular virology and microbiology at Baylor, whose phage therapy work has attracted funding of more than $5 million to date.
The globally research team behind PHIOGEN is housed in the world’s largest medical complex inside the prestigious Texas Medical Center’s Innovation Hub.
PHIOGEN has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle critical and life-threatening infections. This marks a significant medical breakthrough for countering the global threat of antimicrobial resistance.
The World Health Organization deems drug resistant infections as one of the top 10 global public health threats facing humanity with estimates of over 5 million deaths worldwide attributed to antibiotic resistant infections.
The proprietary first-of-its-kind technology platform that is being spearheaded by PHIOGEN is able to discover and screen at-scale naturally occurring bacteriophages, singling out those with elite bacteria-fighting abilities, and directing biological changes to evolve the phage into antimicrobials that overcome resistance.
This creates a new business model for phage therapy as the group is able to create products that treat populations of people instead of on a per patient basis. By optimizing nature’s defenders, the team has produced unprecedented phage treatments which have already successfully saved the lives of several patients in FDA approved, compassionate use cases.
“We receive high-performing phage fighters that are trained and ready to deliver safe and effective treatments for clinical applications,” said Amanda Burkardt, CEO at PHIOGEN.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need
First-of-its-kind vaccine expands malaria protection for pregnant women - Sanaria® PfSPZ Vaccine protects women against malaria before and during pregnancy for at least two years
Bayer awards incubator opportunity to Genvor - Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
Merck and Washington University in St. Louis Sign MoU to Advance Scientific Collaboration - Strategic academic-industry alliance aims to build robust Research & Development talent pipeline
Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina - Facility designed to advance the next generation of imaging systems
QUANTRO Therapeutics extends collaboration with Boehringer Ingelheim - Novel targets in oncology
Giles introduces AI agent to accelerate healthcare and life science research - AI tool connects researchers to verified medical and life sciences global databases, enabling accurate extraction and summarisation of academic papers, journals, and articles
Faster and more reliable crystal structure prediction of organic molecules
Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease
Investigational monoclonal antibody to treat Ebola is safe in adults
